[DFAN14A] STAAR SURGICAL CO SEC Filing
STAAR Surgical Company: Broadwood Partners filed additional proxy materials (DFAN14A) and published an investor presentation urging stockholders to vote on the GREEN Proxy Card against the proposed acquisition of STAAR by an affiliate of Alcon. Broadwood updated its campaign website on October 2, 2025 and issued a press release on October 3, 2025 linking to the materials.
Broadwood states it holds approximately 27.5% of STAAR’s outstanding common stock and cites public opposition from Yunqi Capital, which owns 5.1%. The proxy solicitation relates to the special meeting of stockholders scheduled for October 23, 2025. The definitive proxy statement and GREEN Proxy Card are available on the SEC’s website.
STAAR Surgical Company: Broadwood Partners ha depositato ulteriori materiali di proxy (DFAN14A) e ha pubblicato una presentazione agli investitori invitando gli azionisti a votare sulla GREEN Proxy Card contro la proposta di acquisizione di STAAR da parte di una affiliata di Alcon. Broadwood ha aggiornato il proprio sito della campagna il 2 ottobre 2025 e ha emesso un comunicato stampa il 3 ottobre 2025 collegando i materiali.
Broadwood afferma di detenere circa il 27,5% delle azioni ordinarie in circolazione di STAAR e cita l'opposizione pubblica di Yunqi Capital, che detiene il 5,1%. La sollecitazione alle proxy si riferisce alla riunione speciale degli azionisti prevista per il 23 ottobre 2025. La dichiarazione proxy definitiva e la GREEN Proxy Card sono disponibili sul sito web della SEC.
STAAR Surgical Company: Broadwood Partners presentó material adicional de proxy (DFAN14A) y publicó una presentación para inversores instando a los accionistas a votar con la GREEN Proxy Card contra la propuesta de adquisición de STAAR por parte de una afiliada de Alcon. Broadwood actualizó su sitio web de campaña el 2 de octubre de 2025 y emitió un comunicado de prensa el 3 de octubre de 2025 vinculando al material.
Broadwood afirma poseer aproximadamente el 27,5% de las acciones ordinarias en circulación de STAAR y cita la oposición pública de Yunqi Capital, que posee el 5,1%. La solicitud de proxy se refiere a la reunión especial de accionistas programada para el 23 de octubre de 2025. La declaración proxy definitiva y la GREEN Proxy Card están disponibles en el sitio web de la SEC.
STAAR Surgical Company: Broadwood Partners는 추가 의사록 자료(DFAN14A)를 제출했고 GREEN 의사선거용 카드를 통해 알콘의 자회사에 의한 STAAR 인수 제안에 반대하는 주주 표결을 촉구하는 투자자 프레젠테이션을 게시했습니다. Broadwood는 2025년 10월 2일 캠페인 웹사이트를 업데이트했고 2025년 10월 3일에 자료를 연결하는 보도자료를 발표했습니다.
Broadwood는 STAAR의 발행 보통주 약 27.5%를 보유하고 있다고 밝히며 Yunqi Capital의 공개 반대를 인용하는데, Yunqi Capital은 5.1%를 보유합니다. 의결권 선거는 2025년 10월 23일로 예정된 주주 특별회의와 관련이 있습니다. 확정 의결서와 GREEN Proxy Card는 SEC 웹사이트에서 이용 가능합니다.
STAAR Surgical Company : Broadwood Partners a déposé des documents supplémentaires de procuration (DFAN14A) et publié une présentation destinée aux investisseurs exhortant les actionnaires à voter sur la GREEN Proxy Card contre l'acquisition proposée de STAAR par une affiliée d'Alcon. Broadwood a mis à jour son site de campagne le 2 octobre 2025 et a publié un communiqué le 3 octobre 2025 liant les matériaux.
Broadwood affirme détenir environ 27,5% des actions ordinaires en circulation de STAAR et cite l'opposition publique de Yunqi Capital, qui détient 5,1%. La sollicitation de procuration concerne la réunion extraordinaire des actionnaires prévue le 23 octobre 2025. Le proxy statement définitif et la GREEN Proxy Card sont disponibles sur le site de la SEC.
STAAR Surgical Company: Broadwood Partners legte weitere Proxy-Unterlagen (DFAN14A) vor und veröffentlichte eine Investorenpräsentation, in der die Aktionäre aufgefordert werden, gegen die vorgeschlagene Übernahme von STAAR durch eine Tochtergesellschaft von Alcon mit der GREEN Proxy Card zu stimmen. Broadwood hat seine Kampagnenseite am 2. Oktober 2025 aktualisiert und am 3. Oktober 2025 eine Pressemitteilung veröffentlicht, in der die Materialien verlinkt sind.
Broadwood gibt an, ca. 27,5% der ausstehenden STAAR-Stammaktien zu halten, und verweist auf die öffentliche Gegenstimme von Yunqi Capital, die 5,1% besitzt. Die Proxy-Aufforderung bezieht sich auf die außerordentliche Hauptversammlung der Aktionäre, die für den 23. Oktober 2025 anberaumt ist. Die endgültige Proxy-Statement und die GREEN Proxy Card sind auf der Website der SEC verfügbar.
STAAR Surgical Company: قدمت Broadwood Partners مواد تفويض إضافية (DFAN14A) ونشرت عرضاً تقديمياً للمستثمرين يحث المساهمين على التصويت باستخدام GREEN Proxy Card ضد اقتراح استحواذ STAAR من قبل شركة تابعة لـ Alcon. قامت Broadwood بتحديث موقع الحملة في 2 أكتوبر 2025 وأصدرت بياناً صحفياً في 3 أكتوبر 2025 يربط المواد.
تذكر Broadwood أنها تملك نحو 27.5% من إجمالي أسهم STAAR العادية القابلة للتداول وتذكر المعارضة العامة من Yunqi Capital التي تملك 5.1%. يتعلق طلب التفويض بجلسة المساهمين الخاصة المقررة في 23 أكتوبر 2025. البيان الانتقابي النهائي و GREEN Proxy Card متاحان على موقع هيئة الأوراق المالية الأمريكية (SEC).
STAAR Surgical Company: Broadwood Partners 提交了额外的代理材料（DFAN14A），并发布面向投资者的演示文稿，敦促股东就对 STAAR 被 Alcon 的关联公司提议的收购投票，投票给 GREEN Proxy Card。 Broadwood 于 2025 年 10 月 2 日更新了其竞选网站，并于 2025 年 10 月 3 日发出新闻稿，链接相关材料。
Broadwood 表示其持有 STAAR 已发行普通股约 27.5%，并引用 Yunqi Capital 的公开反对，后者持股 5.1%。 代理征集与拟定于 2025 年 10 月 23 日举行的股东特别大会相关。最终代理声明和 GREEN Proxy Card 可在美国证券交易委员会（SEC）网站得到。
- None.
- None.
Insights
Shareholder with
Broadwood has filed supplemental proxy materials and launched an outreach campaign to oppose STAAR’s proposed sale to an Alcon affiliate. The filing references a dedicated website and an 81-page presentation supporting its position.
The solicitation targets the special meeting on
STAAR Surgical Company: Broadwood Partners ha depositato ulteriori materiali di proxy (DFAN14A) e ha pubblicato una presentazione agli investitori invitando gli azionisti a votare sulla GREEN Proxy Card contro la proposta di acquisizione di STAAR da parte di una affiliata di Alcon. Broadwood ha aggiornato il proprio sito della campagna il 2 ottobre 2025 e ha emesso un comunicato stampa il 3 ottobre 2025 collegando i materiali.
Broadwood afferma di detenere circa il 27,5% delle azioni ordinarie in circolazione di STAAR e cita l'opposizione pubblica di Yunqi Capital, che detiene il 5,1%. La sollecitazione alle proxy si riferisce alla riunione speciale degli azionisti prevista per il 23 ottobre 2025. La dichiarazione proxy definitiva e la GREEN Proxy Card sono disponibili sul sito web della SEC.
STAAR Surgical Company: Broadwood Partners presentó material adicional de proxy (DFAN14A) y publicó una presentación para inversores instando a los accionistas a votar con la GREEN Proxy Card contra la propuesta de adquisición de STAAR por parte de una afiliada de Alcon. Broadwood actualizó su sitio web de campaña el 2 de octubre de 2025 y emitió un comunicado de prensa el 3 de octubre de 2025 vinculando al material.
Broadwood afirma poseer aproximadamente el 27,5% de las acciones ordinarias en circulación de STAAR y cita la oposición pública de Yunqi Capital, que posee el 5,1%. La solicitud de proxy se refiere a la reunión especial de accionistas programada para el 23 de octubre de 2025. La declaración proxy definitiva y la GREEN Proxy Card están disponibles en el sitio web de la SEC.
STAAR Surgical Company: Broadwood Partners는 추가 의사록 자료(DFAN14A)를 제출했고 GREEN 의사선거용 카드를 통해 알콘의 자회사에 의한 STAAR 인수 제안에 반대하는 주주 표결을 촉구하는 투자자 프레젠테이션을 게시했습니다. Broadwood는 2025년 10월 2일 캠페인 웹사이트를 업데이트했고 2025년 10월 3일에 자료를 연결하는 보도자료를 발표했습니다.
Broadwood는 STAAR의 발행 보통주 약 27.5%를 보유하고 있다고 밝히며 Yunqi Capital의 공개 반대를 인용하는데, Yunqi Capital은 5.1%를 보유합니다. 의결권 선거는 2025년 10월 23일로 예정된 주주 특별회의와 관련이 있습니다. 확정 의결서와 GREEN Proxy Card는 SEC 웹사이트에서 이용 가능합니다.
STAAR Surgical Company : Broadwood Partners a déposé des documents supplémentaires de procuration (DFAN14A) et publié une présentation destinée aux investisseurs exhortant les actionnaires à voter sur la GREEN Proxy Card contre l'acquisition proposée de STAAR par une affiliée d'Alcon. Broadwood a mis à jour son site de campagne le 2 octobre 2025 et a publié un communiqué le 3 octobre 2025 liant les matériaux.
Broadwood affirme détenir environ 27,5% des actions ordinaires en circulation de STAAR et cite l'opposition publique de Yunqi Capital, qui détient 5,1%. La sollicitation de procuration concerne la réunion extraordinaire des actionnaires prévue le 23 octobre 2025. Le proxy statement définitif et la GREEN Proxy Card sont disponibles sur le site de la SEC.
STAAR Surgical Company: Broadwood Partners legte weitere Proxy-Unterlagen (DFAN14A) vor und veröffentlichte eine Investorenpräsentation, in der die Aktionäre aufgefordert werden, gegen die vorgeschlagene Übernahme von STAAR durch eine Tochtergesellschaft von Alcon mit der GREEN Proxy Card zu stimmen. Broadwood hat seine Kampagnenseite am 2. Oktober 2025 aktualisiert und am 3. Oktober 2025 eine Pressemitteilung veröffentlicht, in der die Materialien verlinkt sind.
Broadwood gibt an, ca. 27,5% der ausstehenden STAAR-Stammaktien zu halten, und verweist auf die öffentliche Gegenstimme von Yunqi Capital, die 5,1% besitzt. Die Proxy-Aufforderung bezieht sich auf die außerordentliche Hauptversammlung der Aktionäre, die für den 23. Oktober 2025 anberaumt ist. Die endgültige Proxy-Statement und die GREEN Proxy Card sind auf der Website der SEC verfügbar.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934
(Amendment No. )
Filed by the Registrant ☐
Filed by a Party other than the Registrant ☒
Check the appropriate box:
| ☐ | Preliminary Proxy Statement |
| ☐ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
| ☐ | Definitive Proxy Statement |
| ☒ | Definitive Additional Materials |
| ☐ | Soliciting Material under §240.14a-12 |
STAAR Surgical Company
(Name of Registrant as Specified In Its Charter)
Broadwood Partners, L.P.
Broadwood Capital, Inc.
Neal C. Bradsher
Richard T. LeBuhn
Natalie R. Capasso
Raymond A. Myers
Jason J. Martin
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check all boxes that apply):
| ☒ | No fee required |
| ☐ | Fee paid previously with preliminary materials |
| ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 |
On October 2, 2025, Broadwood Partners, L.P. (collectively with its affiliates, “Broadwood”) updated its website, www.LetSTAARShine.com, a copy of which is attached hereto as Exhibit 1 and incorporated by reference. On October 3, 2025, Broadwood issued a press release disclosing its investor presentation titled “The Wrong Time, Wrong Process and Wrong Price,” a copy of the press release is attached hereto as Exhibit 2 and incorporated herein by reference.
CERTAIN INFORMATION CONCERNING THE PARTICIPANTS
Broadwood Partners, L.P., Broadwood Capital, Inc., Neal C. Bradsher, Richard T. LeBuhn, Natalie R. Capasso, Raymond A. Myers and Jason J. Martin (collectively, the “Participants”) are participants in the solicitation of proxies from the stockholders of STAAR Surgical Company (the “Company”) in connection with the special meeting of stockholders scheduled for October 23, 2025 (including any adjournments, postponements, reschedulings or continuations thereof, the “Special Meeting”). The Participants have filed a definitive proxy statement on Schedule 14A (the “Definitive Proxy Statement”) and accompanying GREEN Proxy Card to be used in connection with any such solicitation of proxies from the Company’s stockholders for the Special Meeting. STOCKHOLDERS OF THE COMPANY ARE URGED TO READ THESE MATERIALS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS THAT THE PARTICIPANTS HAVE FILED OR WILL FILE WITH THE SEC BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION, INCLUDING ABOUT THE MATTERS TO BE VOTED ON AT THE SPECIAL MEETING AND ADDITIONAL INFORMATION RELATING TO THE PARTICIPANTS AND THEIR DIRECT OR INDIRECT INTERESTS, BY SECURITY HOLDINGS OR OTHERWISE. The Definitive Proxy Statement and accompanying GREEN Proxy Card have been furnished to some or all of the Company’s stockholders and will be, along with other relevant documents, available at no charge on the SEC’s website at https://www.sec.gov/.
Information about the Participants and a description of their direct or indirect interests, by security holdings or otherwise, is contained on an amendment to Schedule 13D filed by the Participants with the SEC on September 26, 2025 and is available here.
Exhibit 1
RESOURCES Broadwood Materials Broadwood Investor Presentation – October 2 Broadwood Proxy Statement - September 24 Broadwood Letter to Shareholders – September 24 Views of Others Yunqi Capital, 5.1% Holder, Announces Intention to Vote Against the Proposed Sale to Alcon A Commentary by Two Industry Executives SIGN UP FOR UPDATES SUBSCRIBE First Name Last Name Email © 2025 Let STAAR Shine. All rights reserved. Terms of Use. Privacy Policy. Disclaimer. MEDIA August Strategic Communications Scott Deveau / Jeremy Jacobs (323) 805 - 8919 Broadwood@augustco.com INVESTOR CONTACT Saratoga Proxy Consulting, LLC John Ferguson / Joseph Mills (888) 368 - 0379 or (212) 257 - 1311 jferguson@saratogaproxy.com jmills@saratogaproxy.com HOME REASONS TO VOTE AGAINST RESOURCES PRESS/MEDIA HOW TO VOTE CONTACT
Exhibit 2
Oct 3, 2025 6:00 AM Eastern Daylight Time
Broadwood Partners
Publishes Presentation
Detailing Opposition to STAAR Surgical’s Sale to Alcon
Broadwood Believes the Transaction
Comes at the Wrong Time,
After the Wrong Process, and at the Wrong Price
For the Reasons Described in the Presentation, Broadwood Urges All Stockholders to Vote “AGAINST” the Proposed Merger
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood”), holders of approximately 27.5% of the outstanding common stock of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA), today announced that it has published a presentation outlining why stockholders should vote on Broadwood’s GREEN Proxy Card “AGAINST” the proposed acquisition of the Company by an affiliate of Alcon Inc. (NYSE: ALC) on the terms announced on August 5, 2025. The 81-page presentation is available here and on www.LetSTAARShine.com.
Neal Bradsher, President of Broadwood, stated:
“We believe that there was no compelling reason to sell STAAR at this time. Moreover, the Board of Directors failed to conduct a sale process in a responsible manner and ultimately agreed to a price that significantly undervalues STAAR and its bright future. Our presentation provides important new information regarding the deep flaws in this process and valuation.
I am pleased that two other notable stockholders have publicly opposed the transaction: Yunqi Capital Limited, which owns 5.1% of STAAR’s common stock, and David Bailey, the former CEO of STAAR. Before making their voting decisions, all stockholders are encouraged to review our presentation, which describes why this transaction comes at the wrong time, after the wrong process, and at the wrong price.”
About Broadwood
Broadwood Partners, L.P. is managed by Broadwood Capital, Inc. Broadwood Capital is a private investment firm based in New York City. Neal Bradsher is the President of Broadwood Capital.
Certain Information Concerning the Participants
Broadwood Partners, LP., Broadwood Capital, Inc., Neal C. Bradsher, Richard T. LeBuhn, Natalie R. Capasso, Raymond A. Myers and Jason J. Martin (collectively, the “Participants”) are participants in the solicitation of proxies from the stockholders of the Company in connection with the special meeting of stockholders scheduled for October 23, 2025 (including any adjournments, postponements, reschedulings or continuations thereof, the “Special Meeting”). The Participants have filed a definitive proxy statement on Schedule 14A (the “Definitive Proxy Statement”) and accompanying GREEN Proxy Card to be used in connection with any such solicitation of proxies from the Company’s stockholders for the Special Meeting.
STOCKHOLDERS OF THE COMPANY ARE URGED TO READ THESE MATERIALS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS THAT THE PARTICIPANTS HAVE FILED OR WILL FILE WITH THE SEC BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION, INCLUDING ABOUT THE MATTERS TO BE VOTED ON AT THE SPECIAL MEETING AND ADDITIONAL INFORMATION RELATING TO THE PARTICIPANTS AND THEIR DIRECT OR INDIRECT INTERESTS, BY SECURITY HOLDINGS OR OTHERWISE. The Definitive Proxy Statement and accompanying GREEN Proxy Card have been furnished to some or all of the Company’s stockholders and will be, along with other relevant documents, available at no charge on the SEC’s website at https://www.sec.gov/.
Information about the Participants and a description of their direct or indirect interests, by security holdings or otherwise, is contained on an amendment to Schedule 13D filed by the Participants with the SEC on September 26, 2025 and is available here.
Contacts
Investor Contacts
John Ferguson / Joseph
Mills
Saratoga Proxy Consulting LLC
jferguson@saratogaproxy.com
jmills@saratogaproxy.com
(212) 257-1311
(888) 368-0379
Media Contacts
Scott Deveau / Jeremy Jacobs
August Strategic Communications
Broadwood@AugustCo.com
(323) 892-5562
FAQ
What did Broadwood file regarding STAA (NASDAQ: STAA)?
How much of STAAR Surgical does Broadwood say it owns?
When is STAAR Surgical’s special meeting to vote on the deal?
What voting card is Broadwood asking stockholders to use?
Where can STAA stockholders find the definitive proxy materials?
Which other holder publicly opposed the transaction, according to Broadwood?
